The document discusses ChromaDex's forward-looking statements and FDA disclaimer. It then provides an overview of ChromaDex's mission to commercialize patented ingredient technologies, including nicotinamide riboside, pTeroPure, pterostilbene, and anthocyanins, in multi-billion dollar markets like dietary supplements and food and beverage. ChromaDex also has an established legacy business providing analytical testing services and natural products.
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals Daniel Grunstein
Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a target price of NIS 53.2.
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
CBIO Brand Development Inc. is a Vancouver, Canada based HempDerived CBD product company whose manufacturing partner uses a
revolutionary patented pharmaceutical grade ingredient as the base
for all its formulations, for people and their pets. CBIO is currently
commercializing several ailment specific brands for immediate
release into the U.S. wholesale market.
Lupin In Japan- International MarketingHetang Desai
Lupin entering into the Japanese market was a watershed moment in the history of Indian pharmaceutical Industry. The presentation covers the evolution, market share, M&A, Policy, distribution and regulatory systems prevalent at the time.
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals Daniel Grunstein
Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a target price of NIS 53.2.
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
CBIO Brand Development Inc. is a Vancouver, Canada based HempDerived CBD product company whose manufacturing partner uses a
revolutionary patented pharmaceutical grade ingredient as the base
for all its formulations, for people and their pets. CBIO is currently
commercializing several ailment specific brands for immediate
release into the U.S. wholesale market.
Lupin In Japan- International MarketingHetang Desai
Lupin entering into the Japanese market was a watershed moment in the history of Indian pharmaceutical Industry. The presentation covers the evolution, market share, M&A, Policy, distribution and regulatory systems prevalent at the time.
Tech M&A Monthly: 10 Ways to Increase Your Company's ValueCorum Group
If you’re looking at taking advantage of today’s strong M&A market, what can you do to make sure you’re bringing the most valuable company possible to market? There’s no easy trick to building a valuable technology company, but there are specific things that owners and executives can do to maximize that value when preparing for an exit, whether this year or farther down the road. June 9, hear from Corum’s global team of dealmakers for their perspectives as both M&A advisors and CEOs themselves--what they’ve seen drive real value in actual transactions, and how companies like yours can put these best practices to use.
Battling Drug Cartels with Big Data Using LumifyAll Things Open
All Things Open 2014 - Day 1
Wednesday, October 22nd, 2014
Charlie Greenbacker
Director of Data Science for Altamira Technologies Corporation
Big Data
Battling Drug Cartels with Big Data Using Lumify
Find more by Charlie here: http://www.slideshare.net/CharlieGreenbacker
Proxim Tsunami MP11 Series Datasheet(www.quantumwimax.com)Ari Zoldan
ProximWireless is proud to introduce enhanced features to the field-proven Tsunami MP.11 point-to-multipoint product line. The MP.11 series has enabled municipalities and service providers to bridge the digital divide, increase productivity, cut network costs, and create new business opportunities – all through advanced broadband wireless networking.
MeHI Privacy & Security Webinar 3.18.15MassEHealth
Top Reason Why Providers Fail Meaningful Use Audits: Inadequate Security Risk Analysis
Providers are losing incentive dollars by not meeting the Meaningful Use Privacy & Security Measure.
Get on track with your Security Risk Assessment and attest to Meaningful Use with MeHI’s support & solutions:
• Assess your practice’s privacy and security status
• Develop remediation plans to resolve gaps
• Communicate resolution steps to the providers involved
• Track progress in addressing outstanding issues
Let us help you conduct a security risk analysis and address deficiencies and potential threats and ensure that your practice is compliant and that patient data is safe-guarded.
Genimen Pharmacon is the only company in India that holds KFE license.
Genimen Pharmacon is an Indian based biotech company developing a natural and unique nutritional ingredient from kiwifruit. Genimen Pharmacon stands for bioactive compounds from fruits as the word Genimen means Fruit / the Product whereas Pharmacon means biologically active substance.
Genimen is currently seeking funding for the implementation of the development plan leading to an FSSAI approval of health claims and full market access. The development is expected to continue to be supported by public funding. Genimen is extensively trying to raise the fund that provides funding for its corporate activities through 2015.
Going forward we need to forth set our strategic plan in taking the KFE to the end consumers. We welcome rational investors in aiding us financially to take things ahead from here.
Antihyperlipidemic Drugs Market: Overview, Dynamics, Trends, Segmentation, Ap...IMARC Group
IMARC Group's latest report, titled "Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," finds that the global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022. Antihyperlipidemic drugs help in lowering blood lipid levels, including cholesterol.
Global Nutraceuticals Market | Functional Food | Industry Analysis, Size and ...IMARC Group
According to a recently published report by IMARC group titled “Nutraceuticals Market Report” the global personalized nutrition products market was valued at US$ 205 billion in 2015. The market is further divided into personalized food market and personalized beverages market with sales worth US$ 126 Billion and US$ 79 Billion respectively in 2015. Browse Full report with TOC: http://www.imarcgroup.com/nutraceuticals-market
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...RedChip Companies, Inc.
Big North is a graphite development and exploration company with projects in Mexico and Canada
Owns three past producing amorphous graphite mines in Sonora, Mexico
Currently test mining at the Nuevo San Pedro amorphous graphite mine.
Owns high quality large-flake graphite exploration target in Ontario
“The Coin Tree is a cloud-based storage, insurance, and payment processing platform for bitcoin that leverages cutting edge transactional security to serve the ever expanding virtual currency community."
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
DRONE Aviation Corp (DRNE) was formed in April 2014 to penetrate the rapidly growing Unmanned Aerial Systems (UAS) business in U.S. and abroad for government and commercial customers.
DRNE’s mission is to aggressively penetrate the expanding Drone market with our unique Tethered Drones, which are currently being fielded to the U.S. Department of Defense and State and Local municipalities.
DRNE owns and operates Florida-based Lighter Than Air Systems Corp (LTAS), a developer and supplier of unique and specialized aerial solutions to the U.S. Government, State municipalities, and commercial entities.
InterCloud Systems Incorporated is a single - source provider of end - to - end IT technology and telecom solutions to the ent erprise, service provider, and g overnment markets through “Cloud Platforms” and professional services. “Cloud Comput ing”, is defined as the use of computing resources (compute, NTK, Storage) that are delivered as a managed service over a network. InterCloud offers its service provider custo mers the ability to utilize “cloud” solutions inside their existing network footp rint as well as in a “white label environment” so it can offer a suite of cloud products under their own brand, delivered over the broadband services it presently sell s . ICLD’s cloud services include infrastructure as a service (IaaS), platform as a servi ce (PaaS), and software as a service (SaaS) .
The nuclear energy industry has lain stagnant for over 30 years and has suffered from missteps and perception issues.
Lightbridge is here to innovate and change the conversation. About: Lightbridge is a U.S. nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge's breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.
Richfield Oil & Gas Company (OTCQX: ROIL) is an independent exploration and production company headquartered in Salt Lake City, Utah. The Company’s current oil production flows from wells in fields located in Kansas and Wyoming. In addition to several thousand acres in Kansas, Richfield also owns strategically-located exploratory leases in central Utah on trend to major oil discoveries.
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
Founded in 1886, American Water (NYSE: AWK) is the largest publicly traded U.S. water and wastewater utility company. With headquarters in Voorhees, N.J., the company employs approximately 6,600 dedicated professionals who provide drinking water, wastewater and other related services to an estimated 14 million people in more than 40 states and parts of Canada. Our January Online Conference was attended by nearly 5,000 investors. Don't miss your chance to listen to leading small-cap company executives who will provide detailed overviews of their businesses through video presentations and live Q&A sessions.
Exeo Entertainment, Inc. is a manufacturing company concentrating on developing innovative products that fill a clearly defined need in today’s interactive entertainment industry. Featured products include the Zaaz™ smart TV keyboards, Patented Psyko Krypton™ 5.1 gaming headphones, Krankz Bluetooth music headphones, an Android® based portable gaming system, and the Extreme Gamer® -the world’s first multi–disc game changer.
Direct Insite (“DIRI”) provides cloud-based, ERP-agnostic solutions that automate Accounts Payable (AP) and Accounts Receivable (AR) invoice processes for Global 3000 companies. Their solutions include invoice validation, order matching, consolidation, dispute handling and e-payment processing. DIRI helps clients eliminate manual processes and costs associated with doing everything on paper. By migrating from paper to electronic, DIRI can reduce transactions costs 50-70% and reduce time by 80%. Current clients include Siemens, HP, IBM, Saint-Gobain, Shell Oil, and Hyatt with a Global vendor network of 350,000+ suppliers.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
2. Disclaimers
2
Safe Harbor
This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements reflect the
current view about future events. Statements that are not historical in nature, such as our fiscal year 2013 revenue forecast, and which may be identified by the use of
words like “expects,” “assumes,” “projects,” “anticipates,” “estimates,” “we believe,” “could be,” "future" or the negative of these terms and other words of similar
meaning, are forward-looking statements. Such statements include, but are not limited to, statements contained in this presentation relating to our expected sales, cash
flows and financial performance, business, business strategy, expansion, growth, products and services we may offer in the future and the timing of their development,
sales and marketing strategy and capital outlook. Forward-looking statements are based on management’s current expectations and assumptions regarding our
business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict and may
cause actual results to differ materially from those contemplated or expressed. We caution you therefore against relying on any of these forward-looking
statements. These risks and uncertainties include those risk factors discussed in Part I, “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year
ended December 29, 2012 (the “2012 Annual Report”). Any forward-looking statements are qualified in their entirety by reference to the factors discussed in the 2012
Annual Report. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ
significantly from those anticipated, believed, estimated, expected, intended or planned.
Important factors that could cause actual results to differ materially from those in the forward looking statements include: a continued decline in general economic
conditions nationally and internationally; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual
property rights; impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development;
inability to raise capital to fund continuing operations; changes in government regulation, the ability to complete customer transactions and capital raising transactions.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee
future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend
to update any of the forward-looking statements to conform these statements to actual results.
FDA Disclaimer
Statements made in this presentation have not been evaluated by the Food and Drug Administration. ChromaDex products are not intended to treat, cure, prevent or
mitigate any disease. The statements in this presentation are for investor relations and educational purposes only and not intended for consumers or vendors.
3. ChromaDex® Overview/Mission
ChromaDex is currently commercializing four patented and
proprietary ingredient technologies which in aggregate
address multi-billion-dollar markets
Nicotinamide riboside
pTeroPure & caffeine cocrystal
Pterostilbene
Natural black rice extract containing
cyanidin-3-glucoside
ChromaDex is also a leader in providing seamless sciencebased solutions to the dietary supplement, food & beverage,
animal health, cosmetic and pharmaceutical industries.
3
4. ChromaDex® Ingredient Technologies have Commercialization
Opportunities in Multi-billion-dollar Markets
4
Commercialization Opportunity
Size($)
CAGR
Dietary Supplements
30B
7%
Functional Food & Beverage
40B
8%
Animal Health
20B
5%
Cosmetic – Skin Care
25B
6%
950B+
7%
Pharmaceuticals / Medical Foods
Source: Nutrition Business Journal; Vetnosis; Freedonia; RNCOS
Values are estimates and based on 2008-2010 data
Ingredient
Sales
Ingredient Technology
Licensing
5. NIAGEN™ is the 1st and Only Commercially Available
Nicotinamide Riboside
Patents from:
Overview
ChromaDex launched NIAGENTM in May 2013
Nicotinamide Riboside (NR) – The “Miracle Molecule” - is a compound
naturally found in milk and shown to boost nicotinamide adenine
dinucleotide (NAD+) levels. NAD+ is a critical compound that enables
cells to convert fuel to energy and improve mitochondrial function.
NR has potential to be a next-generation, no flush Niacin (Vitamin B3)
and become part of the portfolio of B-vitamin ingredients included in
products serving multi-billion dollar markets such as multi-vitamins,
nutraceuticals, weight-loss, energy drinks, sports nutrition, infant formula,
food & beverage products and anti-aging.
ChromaDex is in the final stages of completing the design
of its 1st human clinical study.
"This study is very important. It shows that in animals, the use of NR offers the health benefits of a lowcalorie diet and exercise — without doing either one.”
The effects of NR on metabolism “are nothing short of astonishing.”
- Researchers at Weill Cornell Medical College and the Polytechnic School in Lausanne, Switzerland1
1 http://www.sciencedaily.com/releases/2012/06/120614182556.htm
5
6. Commercialization of NIAGEN™
NIAGEN™ may have tremendous appeal to the approximately 150 million
Americans who are obese or over weight as well as the 75 million aging
baby boomers in the U.S. – both of which are actively seeking new dietary
supplement solutions for obesity or healthy aging.
ChromaDex believes its patent rights create a significant barrier to entry for
would-be competitors in the NR market.
NIAGEN™ is now available to dietary supplement and food and beverage
companies to include in product formulations.
Thorne Research to market NIAGEN™ to the health-practitioner channel
High Performance Nutrition introduces N(R), featuring NIAGEN™ to support
neuroprotection
In active discussions with several Fortune 500 companies
6
7. NIAGEN™as a Platform
7
Infant Formulas
Dietary
Supplements
Sports Nutrition
Medical Foods
Pharmaceutical
Skincare/Cosmetics
8. NAD+ Research and Studies
Patented vegetarian
Neuroprotection
omega-3•ingredient
• Infant formula
• Weight management
8
•
•
•
•
Weight management
Muscle endurance
Cardio vascular
Diabetes
Dr. Charles Brenner
Dr. Anthony Sauve
• Immune health
• Breast Cancer
Dr. Brunhilde Felding
Dr. Oberdan Leo
• Healthy aging
• Neurodegeneration
Dr. Leonard Guarente
NR is considered by researchers to be the best known precursor to NAD+ production
9. Caffeinated Energy Products have been Coming Under
Increased Regulatory and Political Scrutiny Regarding the
Possible Risks of Consuming High Amounts of Caffeine
March 2012 – a Chicago City Alderman proposed banning energy drinks with at least 180 milligrams of caffeine.
October 2012 – U.S. Senator Richard Blumenthal (D-CT) and U.S. Senator Dick Durbin (D-IL) challenged the Food
and Drug Administration (FDA) to quickly identify and recommend remedies for weaknesses and loopholes in
current law that are exploited by energy drink manufacturers in order to avoid oversight and offer products
containing additives and high levels of caffeine that have not been proven safe.
December 2012 – Canada's regulatory agency, Health Canada, capped the amount of caffeine in energy drinks.
March 2013 – a group of 18 doctors, researchers and public health experts jointly urged the FDA to take action on
energy drinks to protect adolescents and children from the possible risks of consuming high amounts of caffeine.
March 2013 – the American Heart Association Meeting Report cited energy drinks may increase blood pressure and
disturb the heart's rhythm.
May 2013 – San Francisco city attorney sued large energy beverage manufacturer
ChromaDex management believes the market opportunity in the energy beverage market alone is in
excess of $100 million annually.
9
10. PURENERGY™ is a Unique Combination of pTeroPure®
Pterostilbene and Caffeine, Which is Poised to Revolutionize
the Energy Beverage Market
Overview
By cocrystallizing caffeine with pTeroPure ® pterostilbene, caffeine’s energy boost is sustained for
at least 6 hours1
PURENERGY™ also results in a more gradual finish, avoiding the “crash” associated with
traditional caffeine and high-sugar products
Should allow formulators of caffeinated energy products the opportunity to reduce the total
amount of caffeine by as much as 50% without affecting the consumers' product experience
pTeroPure® provides additional health benefits conveniently and readily to the energy market,
including its calming effect
Where can PURENERGY™ deliver results?
Energy boost
Weight loss
Pre-workout & Endurance training
Focus and concentration
1 DATA on file
10
11. PURENERGY™ Clinical Results
11
The cross-over, clinical study compared the cocrystallized caffeine in
PURENERGY™ with ordinary caffeine. The findings of the study
showed:
• PURENERGY™ delivers almost 30% more caffeine into the blood than ordinary caffeine.
• The rate of caffeine absorption is significantly slower with PURENERGY™, by about 30%
as compared to ordinary caffeine
• The half-life of caffeine from PURENERGY™ is extended significantly by about 25% over
that of ordinary caffeine.
• At 4 hours, there was 45% more caffeine from PURENERGY™ compared to ordinary
caffeine alone
• At 6 hours, there was 51% more caffeine from PURENERGY™ compared to ordinary
caffeine alone.
• At 6 hours, subjects taking PURENERGY™ showed significantly less fatigue and greater
concentration compared to baseline. Ordinary caffeine did not.
• At 6 hours, subjects taking PURENERGY™ showed improved energy, alertness and focus
compared to baseline. Ordinary caffeine did not.
• PURENERGY™ showed no adverse events.
12. Blueberries Contain the Powerful Antioxidant Pterostilbene
which ChromaDex® has Developed and is Monetizing its
IP-backed & Clinically-studied Brand, pTeroPure®
12
pTeroPure® is ChromaDex-branded pterostilbene
Pterostilbene is a phytoalexin (plant defense system) found naturally in blueberries, but only in limited quantities
Closely related to resveratrol (an antioxidant found in grapes) but with additional benefits:
More easily enters the blood stream (bioavailability)
Better absorption from the blood stream (cellular uptake)
Effective at activating proteins which help lower cholesterol levels and contribute to anti-aging (bioactivity)
A clinically-tested compound with safety and efficacy data
Awarded Frost & Sullivan’s 2010 “Most Promising Health Ingredient of the Year”
Self-affirmed GRAS1 and launched in the Food & Beverage market; pursuing letter-of-noobjection with FDA
Supported by clinical studies and IP
1
GRAS = Generally Recognized As Safe; requirement for inclusion in food & beverage products
13. pTeroPure® was Evaluated in a Phase 2/3 Clinical Study
Which Showed Statistically Significant Results for Lowering
Blood Pressure
Clinical trial completed at the University of Mississippi
Double-blind, randomized, placebo-controlled, IRB-reviewed
80 patients, 4 arms. Eight-week duration of treatment
Participants in the high-dose pterostilbene group achieved significant reductions in blood pressure
compared to placebo (7.8mm Hg systolic, 7.3mm Hg diastolic)
No serious adverse events
"The results of this study highlight that pterostilbene is a
promising ingredient in the area of cardiometabolics.”
- Daniel M. Riche, PharmD, Cardiometabolic Clinic Coordinator at
the University of Mississippi School of Pharmacy
13
15. ProC3G™ - Anthocyanin
Overview
Anthocyanins are compounds responsible for the deep purple color in
berries, flowers, black rice and other botanicals
Specific anthocyanins have been studied more extensively and have
shown promising health benefits – e.g. cyanidin-3-glucoside (“C3G”)
Potential Health benefits
Weight Loss, Obesity
Insulin resistance / diabetes
Anti-aging
Status
ProC3GTM, ChromaDex-branded 40% C3G (black rice extract), currently
selling in the dietary supplement market
Licensed SUNY Buffalo patent for manufacturing process of pure C3G via
fermentation – development is underway for a new branded ingredient,
AnthoPureTM
Awarded Phase II SBIR grant by NSF for commercialization of SUNYBuffalo process
15
Patents from:
16. ChromaDex® Ingredient Patent Portfolio
16
Issued patent
Ingredient
Technology
• Methods of manufacture
1
2
Nicotinamide
Riboside
Pterostilbenecaffeine cocrystal
•
•
•
•
NAD biosynthesis
Methods of production
Methods of production (2)
Axonal degeneration protection
Patent
Status
Patent pending
Partner
Cornell
Dartmouth
Washington University
• Methods of manufacture
• Composition of matter
Laurus Labs
• Cholesterol reduction (2)
• Oxidative Stress mitigation
• Anti-anxiety treatment
USDA (via University of Mississippi)
• Metabolic, vascular, neurodegenerative (w/ grape extract)
Cott (co-inventor with ChromaDex)
• Non-melanoma skin cancer
UC Irvine (UCI)
• Methods of manufacture
• Crystal polymorph compositions
Laurus Labs
• Metabolic, cardiovascular disease (statin combination)
• Oxidative stress & inflammation (curcumin combination)
ChromaDex inventions
• Methods of manufacture
Research Foundation, SUNY (Buffalo)
3
Pterostilbene
4
Anthocyanins
17. The Legacy Business is a Revenue-generating Platform with
14 Years of Expertise in the Natural Products Industry
Natural product
fine chemicals
Largest phytochemical
catalog in the world
Over 5,000 products
Used for QA & R&D
$3.5M revenue in 2012
Analytical &
chemistry-based services
Analytical testing of
products for identity,
potency, contaminants &
label claims
Revenue $2.8M in 2012
12% CAGR since 2006
Well-Established Customer Base
17
Spherix consulting services
A global leader in scientific
& regulatory consulting
services
Acquired Dec. 2012
18. The Legacy Standards & Analytical Services Business is
Positioned for Growth
18
Increased consumer demand – natural products industry expected
to reach $243B by 20151
Increased R&D by global blue-chip players – e.g. Pepsi Global
Nutrition Group, Nestle Health Sciences
Increased regulatory scrutiny – FDA implementation of GMPs2 and
increased auditing activity
1
2
Global Industry Analysts
GMPs = Good Manufacturing Practices as defined by Code of Federal Regulations
19. ChromaDex’s Unique Business Model
Legacy
19
Established and growing brand
Thousands of customers worldwide
Established Customers
Reference
Standards
Analytical
Services
Research
Materials
Ingredients
Market
Intelligence
University research
Customer order flow
Market trends
Proprietary products
Patent protected
Scientifically backed
High commercial value
20. ChromaDex’s Unique Model Gives it Protected,
First-mover Advantages in Acquiring Ingredient Technologies
Access to Research…
Over 250 University & Research
Institution customers
Insight to Consumer
Markets…
Over 1500 Industry Customers
. . . this combination allows ChromaDex to inexpensively acquire
early-stage Ingredient Technologies with high market potential
20
21. ChromaDex® Discovers, Acquires, & Develops Early-stage
Proprietary Ingredient Technologies and Commercializes them
in Multi-billion-dollar Markets
Discover
Discover novel, early-stage
Ingredient Technologies,
leveraging intelligence
gained from activities of the
legacy business
Acquire
Acquire these
technologies and
associated IP through
licensing & other
collaborations
Develop
Develop a differentiated
offering through:
- Marketing & branding
- Supply chains
- Clinical efforts
- Regulatory status
2
1
Commercialize
Commercialize in multi-billiondollar markets:
- Dietary supplement ($30B)
- Food & Beverage ($40B)
- Animal Health ($20B)
- Cosmeceuticals ($25B)
- Pharmaceuticals (950B+)
22. ChromaDex® is Following the Model of Other Ingredient
Technology Companies
Patented vegetarian
omega-3 ingredient
Acquired by DSM for
$1.08B in 2010
Fish Oil omega-3
Acquired by DSM for
$550M in July 2012
Krill Oil omega-3
Market cap $150-$250M
Ingredient
Acquired by DSM for
$634M in 2012
22
23. ChromaDex® Received Strategic Investment from
DSM Venturing in October 2013
23
$2.5 million common stock investment at $0.85/share
Demonstrates DSM’s confidence in the future of
ChromaDex as well as our unique business model of
acquiring and commercializing novel ingredient technologies
Supports ChromaDex in the expansion of our business
Mutually beneficial relationship
"We are pleased to invest in ChromaDex and thereby support Frank
Jaksch and the entire ChromaDex team in the expansion of their
business. We look forward to a mutually beneficial relationship.”
- Pieter Wolters, Managing Director DSM Venturing
24. ChromaDex® Highlights
24
Focused Expertise
• ChromaDex’s legacy standards & analytical services business
continues to grow at a steady rate as it has over the last 14 years.
• Its expertise in the natural products industry gives the company a
unique platform of market intelligence
• This market intelligence provides access to early-stage Ingredient
Technologies that ChromaDex commercializes across multi-billiondollar markets.
Ingredient Technology Portfolio
• NIAGEN™ shows significant promise as a next-generation Niacin
and enhancer of NAD activity and mitochondrial function
• PURENERGY™ is caffeine alternative that may allow formulators
to reduce caffeine, but not change customer experience
• pTeroPure® pterostilbene, is clinically-studied and sold in the
dietary supplement, food & beverage, and animal health markets
• ProC3G™ have potential for therapeutic effects and as natural food
colorants
26. ChromaDex® At a Glance
Founded 1999 by CEO, Frank Jaksch
Headquarters: Irvine, CA
Analytical Laboratory: Boulder, CO
- Acquired in April 2003 from NaPro
BioTherapeutics
Regulatory Consulting: Rockville, MD
- Acquired Spherix Consulting in
December 2012
Employees: Approximately 80
Publicly-listed in 2008
Symbol: CDXC
26
Irvine, CA
Boulder, CO
Total Shares Outstanding1 – 104.8M (119.0M including options and warrants)
12-month trading range: $0.48 – $1.25
43% growth in year-over-year revenue:
– 2011 - $8.1M
– 2012 - $11.6M
1
As of 11/27/2013
27. ChromaDex® Management Team
Frank Jaksch
Co-Founder, CEO, Director
Founded ChromaDex in 1999
Int’l Subsidiaries Manager at Phenomenex
Expertise in analytical chemistry, product development
Recognized industry expert, most recently appearing
on Dateline NBC’s Hansen Files regarding quality
testing in the natural products industry
Board of Directors, Natural Products Association
B.S. Biology & Chemistry, Valparaiso
Member, NSF Joint Committee for Dietary
Supplements, American Chemistry Society,
American Herbal Products Association
Tom Varvaro – Chief Financial Officer
Mark Jost – VP of Operations
Troy Rhonemus – Director of New Technology & Supply Chain
Mark Morris – VP of Sales & Marketing
Greg Sowards – VP of Business Development
Dr. Sylesh Venkataraman – Senior Director, Laboratory
27
28. Shareholder Summary
28
Number of Shares
Percent
Ownership1
Dr. Phillip Frost
Opko Health, Inc.
(NYSE:OPK)
15,252,937
14.55%
1,833,333
1.75%
DSM Venturing B.V.
Frank L. Jaksch Jr.
(Founder, CEO, Director)
Other Directors and
Officers
2,941,176
2.81%
7,993,320
7.62%
17,731,494
16.91%
Total Insider Ownership
25,724,814
24.53%
SUBTOTAL
45,752,260
43.64%
Shareholder
1
Based on 104.8M shares outstanding as of 11/27/2013
29. ChromaDex® Model in Action – pTeroPure®
Case Study
Acquire
Discover
2003: Collaborates
with USDA to provide
reference standards for
R&D (legacy business
activity)
2003-2012: Obtains
exclusive access to USDA
research & begins
collaborating on
pterostilbene development
2003: Learns about USDA’s
research on pterostilbene, a
novel compound found in
blueberries, through
relationship with researcher
Dr. Agnes Rimando
Develop
2009: Partners with
manufacturer to
achieve commercialscale production of
pterostilbene; licenses
manufacturing patent
2010: Licenses USDA IP on
use of pterostilbene for
various therapeutic effects
29
Commercialize
2012: Partners
with Glanbia to
expand distribution
2011: Launches
,
a breakthrough dietary supplement
featuring
2012: Completes
clinical study
proving safety &
blood pressure
reduction
2013: Complete sale of
to NeutriSci
2010: Launches
as a
novel, proprietary ingredient for the
dietary supplement and Food &
Beverage markets
30. ChromaDex® Ingredient Technology Portfolio
30
Monetization
Branded Ingredient
Compound
Supply
Safety
Clinical
Development
Dietary
Supplements
Food &
Beverage
Animal
Health
1
Pterostilbene
1st study
complete
2
3
Pterostilbenecaffeine
cocrystal
Nicotinamide
Riboside
4
Anthocyanins
Next-generation products for multiple applications are in development
Skin
Care
Pharma
31. Contact Information
31
ChromaDex, Inc.
10005 Muirlands Blvd., Suite G
Irvine, CA 92618
Phone: +1-949-419-0288
Fax: +1-949-419-0294
www.chromadex.com
Investor Relations
Bob Prag, President
The Del Mar Consulting Group, Inc.
Phone: 858.794.9500
bprag@delmarconsulting.com
Scott Wilfong, President
Alex Partners, LLC
Phone: 425.242.0891
scott@alexpartnersllc.com